Agile Therapeutics, Inc.
AGRX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $4 | $5 | $1 | $243 |
| - Cash | $3 | $5 | $19 | $14 |
| + Debt | $2 | $2 | $18 | $17 |
| Enterprise Value | $4 | $2 | -$0 | $245 |
| Revenue | $20 | $11 | $4 | $1 |
| % Growth | 80% | 165.4% | 447.5% | – |
| Gross Profit | $11 | $4 | -$7 | $0 |
| % Margin | 54.2% | 37.2% | -161.4% | 62.3% |
| EBITDA | -$13 | -$25 | -$65 | -$48 |
| % Margin | -64.6% | -233.6% | -1,583.3% | -6,471% |
| Net Income | -$14 | -$25 | -$77 | -$55 |
| % Margin | -73.8% | -233.5% | -1,867.5% | -7,301.2% |
| EPS Diluted | -6.71 | -58.79 | -63,115.49 | -1,291.56 |
| % Growth | 88.6% | 99.9% | -4,786.8% | – |
| Operating Cash Flow | -$10 | -$36 | -$65 | -$47 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$10 | -$36 | -$65 | -$48 |